Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60, EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature Medicine.
After the close biotech stocks were mixed with some notable winners: BPMC, ECYT, IONS, SGEN.
========
Mid-Cap Biotechs: Performance Post ASCO
We will update our biotech mid-cap performance list on Tuesday but here are the momentum leaders near 52 week highs after ASCO news and updates.We will also update our mid-cap list at the six month mark.
ETFs: FBT,QQQ,XBI
52 Week leaders
AGIO, ARRY, CRSP, FMI, FOLD, GWPH, LGND, LOXO, NBIX, SGEN, SRPT
52 Week laggards
ACAD, ANAB, CLVS, EXEL, INCY, IONS, TSRO